[go: up one dir, main page]

IS2070B - Stöðugar interferónlyfjablöndur á vökvaformi - Google Patents

Stöðugar interferónlyfjablöndur á vökvaformi

Info

Publication number
IS2070B
IS2070B IS5087A IS5087A IS2070B IS 2070 B IS2070 B IS 2070B IS 5087 A IS5087 A IS 5087A IS 5087 A IS5087 A IS 5087A IS 2070 B IS2070 B IS 2070B
Authority
IS
Iceland
Prior art keywords
liquid
interferon
compositions
beta
continuous liquid
Prior art date
Application number
IS5087A
Other languages
English (en)
Icelandic (is)
Other versions
IS5087A (is
Inventor
Mary D Dibiasi
Staples Mark
Chung Wen-Li
Scharin Eric
Original Assignee
Biogen Ides Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2070(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ides Ma Inc filed Critical Biogen Ides Ma Inc
Publication of IS5087A publication Critical patent/IS5087A/xx
Publication of IS2070B publication Critical patent/IS2070B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5087A 1996-12-24 1999-06-21 Stöðugar interferónlyfjablöndur á vökvaformi IS2070B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (2)

Publication Number Publication Date
IS5087A IS5087A (is) 1999-06-21
IS2070B true IS2070B (is) 2005-12-15

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5087A IS2070B (is) 1996-12-24 1999-06-21 Stöðugar interferónlyfjablöndur á vökvaformi

Country Status (27)

Country Link
EP (1) EP0948358B2 (et)
JP (5) JP4878664B2 (et)
KR (2) KR20000069664A (et)
CN (2) CN1222315C (et)
AT (1) ATE270899T1 (et)
AU (1) AU738362B2 (et)
BG (2) BG65171B1 (et)
BR (1) BR9714434A (et)
CA (1) CA2275890C (et)
CZ (1) CZ300636B6 (et)
DE (1) DE69729880T3 (et)
DK (1) DK0948358T4 (et)
EA (1) EA002754B1 (et)
EE (2) EE04223B1 (et)
ES (1) ES2224290T5 (et)
HU (1) HU224222B1 (et)
IL (1) IL130524A (et)
IS (1) IS2070B (et)
MX (1) MX337876B (et)
NO (1) NO327844B1 (et)
NZ (2) NZ336548A (et)
PL (1) PL193447B1 (et)
PT (1) PT948358E (et)
SI (1) SI0948358T2 (et)
SK (1) SK284989B6 (et)
TR (1) TR199901968T2 (et)
WO (1) WO1998028007A1 (et)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
IL130524A (en) * 1996-12-24 2005-08-31 Biogen Idec Inc Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same
IL135186A0 (en) 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
HK1044471A1 (en) * 1999-05-31 2002-10-25 Mitsubishi Chemical Corporation Freeze dried hgf preparations
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
WO2003061687A1 (fr) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation Preparation a concentration elevee de thrombomoduline soluble
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
ATE454900T1 (de) 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP2007519623A (ja) 2003-12-19 2007-07-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの安定化された組成物
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587061C (en) * 2004-11-10 2011-08-16 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
EP1845925B1 (en) 2005-01-12 2016-08-24 Biogen MA Inc. Method for delivering interferon-beta
CN101106979A (zh) * 2005-01-21 2008-01-16 阿尔扎公司 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂
EP2264162A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
CA2707484C (en) * 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
HRP20120483T1 (hr) 2007-12-20 2012-07-31 Merck@Serono@SA Formulacije peg interferona beta
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CA2726824A1 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
KR101912169B1 (ko) 2010-02-04 2018-10-26 체에스엘 베링 아게 면역글로불린 제제
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP5538568B2 (ja) * 2010-12-09 2014-07-02 丸石製薬株式会社 アセトアミノフェンの安定化剤
ES2666850T3 (es) * 2011-03-15 2018-05-08 Biogen Ma Inc. Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP2015515480A (ja) * 2012-04-19 2015-05-28 シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ エチレンオキシド滅菌下のｐＨ安定性が改善された注入液
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
AU2015357068B2 (en) 2014-12-03 2021-07-29 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
US20230159605A1 (en) * 2020-04-29 2023-05-25 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
KR20230164127A (ko) * 2021-03-30 2023-12-01 쇼트 파마 슈바이츠 아게 의약품 조성물의 저온 저장용 시스템, 액체 조성물, 방법 및 용도
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
MX2024008162A (es) * 2021-12-27 2024-09-17 Enalare Therapeutics Inc Formulaciones parenterales estimulantes respiratorias.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (et) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
IL130524A (en) * 1996-12-24 2005-08-31 Biogen Idec Inc Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same

Also Published As

Publication number Publication date
JP2007204501A (ja) 2007-08-16
CZ228299A3 (cs) 1999-12-15
AU738362B2 (en) 2001-09-13
NO327844B1 (no) 2009-10-05
CN1733296B (zh) 2010-05-26
HUP0000829A3 (en) 2002-01-28
NZ336548A (en) 2001-09-28
CZ300636B6 (cs) 2009-07-08
DK0948358T4 (da) 2012-03-19
SI0948358T1 (en) 2005-04-30
HK1025040A1 (en) 2000-11-03
NO993121L (no) 1999-08-24
DE69729880D1 (de) 2004-08-19
DE69729880T2 (de) 2005-07-07
IS5087A (is) 1999-06-21
SI0948358T2 (sl) 2012-03-30
BG65171B1 (bg) 2007-05-31
JP2011068694A (ja) 2011-04-07
SK284989B6 (sk) 2006-04-06
BR9714434A (pt) 2000-05-02
AU5619198A (en) 1998-07-17
BG65418B1 (bg) 2008-07-31
EE200300127A (et) 2003-06-16
BG103594A (en) 2000-04-28
MX337876B (es) 2016-03-22
EE04266B1 (et) 2004-04-15
ES2224290T5 (es) 2012-03-12
EP0948358A1 (en) 1999-10-13
ES2224290T3 (es) 2005-03-01
EE04223B1 (et) 2004-02-16
HU224222B1 (hu) 2005-06-28
HUP0000829A2 (en) 2000-07-28
JP4878664B2 (ja) 2012-02-15
JP5851695B2 (ja) 2016-02-03
DE69729880T3 (de) 2012-05-10
JP2001519770A (ja) 2001-10-23
BG109523A (en) 2007-05-31
SK85899A3 (en) 2000-01-18
KR20000069664A (ko) 2000-11-25
PT948358E (pt) 2004-10-29
CA2275890C (en) 2011-11-01
JP2012006979A (ja) 2012-01-12
DK0948358T3 (da) 2004-11-08
EP0948358B1 (en) 2004-07-14
EA002754B1 (ru) 2002-08-29
KR101042660B1 (ko) 2011-06-20
CN1733296A (zh) 2006-02-15
EP0948358B2 (en) 2011-11-23
PL334365A1 (en) 2000-02-28
IL130524A0 (en) 2000-06-01
CN1245434A (zh) 2000-02-23
IL130524A (en) 2005-08-31
EE9900313A (et) 2000-04-17
PL193447B1 (pl) 2007-02-28
ATE270899T1 (de) 2004-07-15
NZ512792A (en) 2002-11-26
EA199900597A1 (ru) 2000-02-28
HK1092048A1 (zh) 2007-02-02
CN1222315C (zh) 2005-10-12
NO993121D0 (no) 1999-06-23
WO1998028007A1 (en) 1998-07-02
JP2014098029A (ja) 2014-05-29
CA2275890A1 (en) 1998-07-02
KR20070052363A (ko) 2007-05-21
TR199901968T2 (xx) 1999-12-21

Similar Documents

Publication Publication Date Title
IS2070B (is) Stöðugar interferónlyfjablöndur á vökvaformi
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2032499A1 (en) Polypeptide derivatives
CA2094027A1 (en) Osteogenic peptides
AU586892B2 (en) Pharmaceutical and dietary composition
EP1197220A3 (en) Therapeutic methods and compositions based on delta proteins and nucleic acids
AU1094892A (en) Improved activation of recombinant proteins
ZA941198B (en) Highly concentrated TCF pharmaceutical preparations
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0723016A3 (en) Leukocyte activation factor
CA2153071A1 (en) Derivatized calcitonins
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.